Analytical Data
-
Gene name
CXCL17
- Application
-
Alternative Names
CXCL17；VCC1;C-X-C motif chemokine 17
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q6UXB2
-
Expression Region
22-119aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MSSLNPGVAR GHRDRGQASR RWLQEGGQEC ECKDWFLRAP RRKFMTVSGL PKKQCPCDHF KGNVKKTRHQ RHHRKPNKHS RACQQFLKQC QLRSFALPL
-
Molecular Weight
14 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CXCL17, a member of the CXC chemokine family, has garnered attention due to its unique structural and functional characteristics. Initially identified for its role in immune response, CXCL17 is primarily expressed by various cell types, including epithelial cells and macrophages, and plays a significant role in mediating the recruitment of immune cells to sites of infection or inflammation. Research has shown that CXCL17 is involved in various pathological processes, including cancer progression, autoimmune diseases, and chronic inflammatory conditions. Its ability to bind to the chemokine receptor CXCR8 suggests a crucial role in modulating immune responses. Recent studies have focused on the production of recombinant CXCL17 protein to better understand its biological functions and potential therapeutic applications. By employing recombinant DNA technology, researchers aim to generate a stable supply of CXCL17 for in vitro and in vivo studies. These investigations seek to elucidate the signaling pathways activated by CXCL17, its role in tumor microenvironments, and its potential as a biomarker for disease progression. Additionally, understanding the structure-activity relationship of CXCL17 could pave the way for novel drug development aimed at manipulating its activity for therapeutic benefits. Given the increasing recognition of chemokines in the context of cancer immunotherapy and other disease treatments, the study of CXCL17 and its recombinant protein will likely contribute important insights into the intricate interplay between the immune system and disease pathogenesis.
